Akero Therapeutics
CA - South SFBiotechnology
Focus: Akero Therapeutics is a clinical-stage biotech focused on NASH/MASH (metabolic dysfunction-associated fatty liver disease), a high-unmet-need metabolic disease with significant market opportunity. The company is headquartered in South San Francisco and operates as a dedicated asset-development organization.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Open Jobs
0
About Akero Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Akero Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
efruxifermin
NASH/MASHClinical Trials (5)
NCT06215716A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Phase 3Help build intelligence for Akero Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.